ArticleTherapie
Efficacy of COVID-19 vaccines: From clinical trials to real life.
Article in Therapie. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Determinants of COVID-19 Vaccine Engagement in Algeria: A Population-Based Study With Systematic Review of Studies From Arab Countries of the MENA Region.Frontiers in public health · 2022Pooled it
- Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Pooled it
- An extension of the Benefit Risk Assessment of VaccinEs toolkit to evaluate Comirnaty and Spikevax vaccination in the European Union.European journal of public health · 2025Article
- Real-World Effectiveness of COVID-19 Vaccines (ChAdOx-1s, CoronaVac, BBIBP-CorV, mRNA-1273, and BNT162b2) in Jakarta: Protocol for Test-Negative Design of Health Care Data.JMIR research protocols · 2025Article
- Real-world impact of COVID-19 vaccination, household exposure, and circulating SARS-CoV-2 variants on infection risk and symptom presentation in a U.S./Mexico border community.Frontiers in public health · 2025Article
- Vaccination and Its Impact on Lung Involvement in COVID-19 Patients: A Retrospective Study in India.Cureus · 2024Article
- Uptake of COVID-19 vaccine among high-risk urban populations in Southern Thailand using the COM-B model.PloS one · 2024Article
- Points to consider in the development of national human genome editing policy.Cambridge prisms. Precision medicine · 2023Review
- The race Against Time to Save Human Lives During the COVID-19 With Vaccines: Global Evidence.Evaluation review · 2022Article
- Understanding the epigenetic mechanisms in SARS CoV-2 infection and potential therapeutic approaches.Virus research · 2022Review
- Medical Liability of the Vaccinating Doctor: Comparing Policies in European Union Countries during the COVID-19 Pandemic.International journal of environmental research and public health · 2022Review
- Unmet need for COVID-19 vaccination coverage in Kenya.Vaccine · 2022Article
- Hospital acquired COVID-19 infections amongst patients before the rollout of COVID-19 vaccinations, a scoping review.BMC infectious diseases · 2022Article
- Efficacy of COVID-19 vaccines: Several modes of expression should be presented in scientific publications.Fundamental & clinical pharmacology · 2022Article
- COVID-19 status quo: Emphasis on gastrointestinal and liver manifestations.World journal of gastroenterology · 2021Review
- An Exploratory Review of Potential Adjunct Therapies for the Treatment of Coronavirus Infections.Journal of chiropractic medicine · 2021Review
- Article
- An Understanding of the Drivers of Infectious Diseases in the Modern World Can Aid Early Control of Future Pandemics.Pharmacy (Basel, Switzerland) · 2021Article
- [Statistical literacy and risk communication for COVID-19 vaccination: a scoping reviewLiteracia estatística e comunicação de risco para a vacinação contra a COVID-19: revisão de escopo].Revista panamericana de salud publica = Pan American journal of public health · 2021Article
- Article
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread around the globe leading to the COVID-19 pandemic. To mitigate the effects of the virus on public health and the global economy, vaccines were rapidly developed. In less than one year, with respect to usual clinical development rules, several vaccines have been put on the market and mass vaccination campaigns have been deployed. During the phase I to phase III clinical trials, most of these vaccines have demonstrated both their safety and efficacy. Despite questions remain about the impact of virus variants and the duration of the immune response, messenger RNA (mRNA)-based and adenoviral vectored vaccines have demonstrated an overall efficacy from 70 to 95% in both phase III trials and real life. In addition, all these vaccines also reduce the severe forms of the disease and might strongly impact the mortality which could change the course of the pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.